New pill vs. infusion: which works better for severe colitis?
NCT ID NCT07550673
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two drugs—upadacitinib (a pill) and infliximab (an infusion)—as second-line treatments for acute severe ulcerative colitis. About 226 adults will be randomly assigned to one of the two drugs for 3 months. The main goal is to see if upadacitinib can reduce symptoms like bloody diarrhea and frequent bowel movements as effectively as infliximab by day 7.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
upadacitinib and infliximab
What this could lead to
If upadacitinib works as well as infliximab, it could offer a new second-line option for people with severe ulcerative colitis who don't respond to first treatment.
What could go wrong
This is an early-phase 4 trial with 226 participants, so results may not apply to everyone. Both drugs have known risks like infection and allergic reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE SEVERE ULCERATIVE COLITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
3201 Hospital
RECRUITINGHanzhong, Shaanxi, 710005, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Ankang Central Hospital
RECRUITINGAnkang, Shaanxi, 725000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shaanxi Provincial Nuclear Industry 215 Hospital
RECRUITINGXianyang, Shaanxi, 712000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Xijing Hosipital of Digestive Disease
RECRUITINGXi'an, Shaanxi, 710005, China
Contact Phone: •••-•••-•••• Email: •••••@•••••